(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 March 2010 (11.03.2010)

PCT

(10) International Publication Number
WO 2010/027431 A1

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61P 29/00* (2006.01)
A61K 31/407 (2006.01) *A61P 31/12* (2006.01)
A61K 31/437 (2006.01) *A61P 37/00* (2006.01)

(21) International Application Number:
PCT/US2009/004851

(22) International Filing Date:
26 August 2009 (26.08.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/190,311 27 August 2008 (27.08.2008) US
61/269,519 24 June 2009 (24.06.2009) US

(71) Applicant *(for all designated States except US)*: **ARENA PHARMACEUTICALS, INC.** [US/US]; 6166 Nancy Ridge Drive, San Diego, California 92121-3223 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **JONES, Robert, M.** [GB/US]; 10937 Corte luz del Sol, San Diego, California 92130 (US). **BUZARD, Daniel, J.** [US/US]; 14494 Janal Way, San Diego, California 92129 (US). **KAWASAKI, Andrew, M.** [US/US]; 10554 Abalone Landing Terrace, San Diego, California 92130 (US). **KIM, Sun, Hee** [KR/US]; 8936 Revelstoke Way, San Diego, California 92126 (US). **THORESEN, Lars** [US/US]; 7130 Shoreline Drive, No. 1110, San Diego, California 92122 (US). **LEHMANN, Juerg** [CH/US]; 9840 La Tortola Ct., San Diego, California 92129 (US). **ZHU, Xiuwen** [CN/US]; 11367 Black Colt Lane, San Diego, California 92130 (US).

(74) Agents: **SPRUCE, Lyle, W.** et al.; Arena Pharmaceuticals, Inc., 6166 Nancy Ridge Drive, San Diego, California 92121-3223 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) **Title**: SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS



(I)

(57) **Abstract**: The present invention relates to certain substituted tricyclic acid derivatives of Formula (I) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, myocardial ischemia-reperfusion injury injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, biliary cirrhosis, microbial infections and associated diseases, viral infections and associated diseases, diseases and disorders mediated by lymphocytes, auto immune diseases, inflammatory diseases, and cancer.

WO 2010/027431 A1